Massive Sell-Offs Just Hit These 10 Stocks Today

8. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma saw its share price decline by 6.78 percent on Tuesday to finish at $33.26 each following President Donald Trump’s new executive order directing drugmakers to lower the prices of drugs.

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company, dropped alongside its counterparts in the healthcare sector as investors feared that the new order would dent  the profits and margins of drugmakers and retailers.

In recent news, BridgeBio Pharma, Inc. (NASDAQ:BBIO) widened its net loss by 371 percent to $169.6 million in the first quarter of the year from $36 million in the same period a year earlier, while revenues fell by 45 percent to $116 million from $211 million year-on-year.  Of the total revenue, $36.7 million was attributed to Attruby.

Meanwhile, the company was gaining strong traction for its heart treatment, Attruby, having recorded 2,072 prescriptions written by 756 prescribers as of April 25.